Compare Honeywell Aerospace Inc. Common Stock (HONA) vs ImmunityBio Inc. Common Stock (IBRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell Aerospace Inc. Common Stock vs ImmunityBio Inc. Common Stock — how do they compare? Honeywell Aerospace Inc. Common Stock trades at $155.75 (market cap $50.14B), while ImmunityBio Inc. Common Stock trades at $10.09 (market cap $10.39B). The key difference: Honeywell Aerospace Inc. Common Stock is far larger — about 4.8× ImmunityBio Inc. Common Stock's market cap, and ImmunityBio Inc. Common Stock is trading nearer its 52-week high, Honeywell Aerospace Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Honeywell Aerospace Inc. Common Stock for 0 Days and ImmunityBio Inc. Common Stock for 6 Days on average.
| HONA | IBRX | |
|---|---|---|
Market Cap | $50.14B | $10.39B |
Volume | 1,433,364 | 11,509,049 |
Sector | Industrials | Health |
52-Week High | $269.95 | $11.55 |
52-Week Low | $151.58 | $1.98 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $64.96B | $10.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HONA trades at $158.18, up 0.58% today, with neutral technical indicators showing support at $156 and resistance at $160. The company reported Q2 2026 EPS of $1.87, missing expectations of $2.07, while revenue grew to $17.40B in 2025. Analyst consensus remains mixed with a $211.25 price target, but multiple class action lawsuits filed in October 2026 create significant legal overhang.
HONA faces near-term headwinds from earnings miss and legal challenges, though strong cash flow generation and analyst price targets suggest long-term potential. Investors should weigh the 42.9% buy rating against litigation risks and declining profit margins projected for 2026.
ImmunityBio (IBRX) trades at $9.80, down 3.16% on the day, amid a bullish technical setup and strong analyst support. The company reported revenue growth to $166 million in 2026 but remains deeply unprofitable with a net loss of $992 million. Recent FDA approval expansion for ANKTIVA in bladder cancer and high-profile executive appointments signal operational momentum, though cash burn remains a concern with negative operating cash flow.
Outlook is cautiously optimistic given the unanimous buy ratings and regulatory milestones, but investment carries high risk due to persistent losses, heavy reliance on financing, and competitive pressures. The stock's trajectory hinges on successful commercialization and pipeline execution to achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Honeywell Aerospace Inc. Common Stock
Honeywell Aerospace Inc. is an aerospace and defense technology company, spun off from Honeywell in June 2026, that designs and supplies avionics, propulsion components (including auxiliary power units and engines), and connectivity systems for commercial, defense, and space aircraft.
Read more on HONA →About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →
